Loading patent…
AssigneeUniversity of Iowa Research Foundation
InventorsJinhua Xiang, Sabina Wunschmann, Warren Schmidt, Jack Stapleton
Estimating the term…
GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.
An isolated and purified nucleic acid molecule encoding an infectious GBV-C.
A method of preparing an infectious GBV-C comprising:
An infectious GBV-C produced by a method comprising:
A method of inhibiting HIV disease progression in a subject infected with HIV comprising administering to the subject an effective amount of an isolated and purified nucleic acid molecule encoding an infectious GBV-C sequence.
A method of inhibiting HIV infection in a subject comprising administering to the subject an effective amount of an isolated and purified nucleic acid molecule encoding an infectious GBV-C.
A method of inhibiting a cell infected with HIV comprising administering to the cell an effective amount of an isolated and purified nucleic acid molecule encoding a GBV-C polypeptide in an amount effective to inhibit HIV replication in the cell.
A method of treating a subject infected with HIV comprising administering to a cell of the subject an effective amount of an infectious GBV-C comprising a heterologous nucleic acid sequence.
A method of treating a subject infected with HIV comprising administering to the subject an effective amount of an expression construct comprising a GBV-C sequence, wherein said subject is provided a therapeutic benefit.
A method of expressing a heterologous nucleic acid sequence comprising providing to a cell an isolated and purified nucleic acid molecule encoding an infectious GBV-C sequence and the heterologous nucleic acid sequence.
A method of producing an immune response in a subject comprising administering to the subject an amount of an expression construct comprising GBV-C sequences and a heterologous nucleic acid sequence operably linked to a promoter, wherein the heterologous nucleic acid sequence encodes a polypeptide, effective to elicit an immune response against the polypeptide.
Dependencies are inferred from the claim text.